Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactiplantibacillus plantarum CBT LP3 + Bifidobacterium breve CBT BR3
- Development stage
- Preclinical
- Lead developer
- Cell Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A mixed probiotic formulation composed of the live bacterial strains **Lactiplantibacillus plantarum CBT LP3** and **Bifidobacterium breve CBT BR3**, investigated primarily for anti-obesity effects through modulation of the gut microbiota and downstream metabolic and endocrine markers. Publicly described in a 2024 *Scientific Reports* study in overweight and obese dogs, oral supplementation over 12 weeks was associated with reductions in body weight, body condition score, serum triglycerides, total cholesterol, and leptin, with increased adiponectin and shifts in fecal microbial composition. The program appears to be associated with Cell Biotech-origin CBT strains and represents a live microbial therapeutic or nutraceutical-style probiotic combination rather than a conventional small-molecule pharmaceutical.
- Other names
- Lactiplantibacillus plantarum CBT LP3 + Bifidobacterium breve CBT BR3Lactobacillus plantarum CBT LP3 + Bifidobacterium breve CBT BR3
Beyond the preview
Go deeper on Lactiplantibacillus plantarum CBT LP3 + Bifidobacterium breve CBT BR3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactiplantibacillus plantarum CBT LP3 + Bifidobacterium breve CBT BR3.